OSR Holdings subsidiary Vaximm gets binding term sheet for VXM01 license: $30M upfront, $815M milestones

OSR Holdings, Inc.

Vaximm, OSR Holdings' subsidiary, enters binding term sheet with BCM Europe for global exclusive license of VXM01.
Upfront payment of $30M (50% cash, 50% digital assets) and up to $815M in clinical, regulatory, and commercial milestones.
Definitive agreement targeted by end of May 2026, subject to fairness opinion, board review, and final documentation.
BCM Europe, the largest OSRH shareholder, will establish a fund (BCM Decentralized Science Investors I) as licensee.
VXM01 is an oral T-cell vaccination platform targeting VEGFR-2; has shown clinical activity and safety in multiple cancers.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.92

OSR Holdings, Inc. entered into Binding Term Sheet with BCM Europe AG valued at $30.0 million (comprised of $15.0 million in cash and $15.0 million in digital assets) and up to $81 (effective 2025-01-13).

Action: entry
Agreement: license
Counterparty: BCM Europe AG
Value: $30.0 million (comprised of $15.0 million in cash and $15.0 million in digital assets) and up to $81
Effective: 2025-01-13

Exact text from the filing

On January 13, 2025, Vaximm AG, a wholly-owned subsidiary of OSR Holdings, Inc. (the “Company”), entered into a Binding Term Sheet (the “Term Sheet”) with BCM Europe AG (“BCME”), the largest shareholder of the Company, relating to a proposed global exclusive license of Vaximm’s VXM01 oral cancer immunotherapy platform.

View on SEC.gov

294 material agreements filed in the last 30 days. Browse all material agreements →

OSR Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-004199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.